ArticleBMC pharmacology & toxicology2025
Surfactant-driven modulation of protein corona on solid lipid nanoparticles: Insights including molecular docking studies.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanoparticles have been used in nanomedicine for therapeutic purposes. Lipids have been a popular choice of material in the synthesis of biocompatible nanoparticles due to their ability to encapsulate diverse therapeutic agents. However, once introduced into biological environments, nanoparticles rapidly adsorb proteins on their surface, forming a protein corona that can alter drug release, targeting and cellular interactions. Understanding these effects is essential for optimizing solid lipid nanoparticles (SLNs) as drug delivery systems.
methodsSLNs were synthesized using stearic acid (SA) as the lipid core and stabilized with surfactants, Tween 80 and SDS (sodium dodecyl sulphate). To mimic in vitro conditions, SLNs were incubated with 5% FBS (foetal bovine serum) for varying durations to allow soft and hard protein corona formation. SLNs were characterized for size and surface charge via dynamic light scattering while UV visible spectroscopy, protein adsorption studies, FTIR and the Bradford Assay were employed to confirm and quantify protein corona formation. In parallel, molecular docking was conducted to analyse protein-nanoparticle interactions. To investigate the potential influence of protein corona formation on drug release, ceftriaxone (CTX) was encapsulated within SLNs followed by immediate incubation to allow corona formation. Subsequent evaluations included drug leakage, release profile and antibacterial efficacy against Staphylococcus aureus and Pseudomonas aeruginosa.
resultsProtein adsorption was confirmed on all SLN formulations and closely correlated with nanoparticle surface charge. Formulations with more negative zeta potentials adsorbed higher amounts of protein. SDS concentration influenced protein adsorption with higher SDS content reducing overall corona formation. Molecular docking revealed that protein-ligand interactions were maintained by hydrogen bonding and hydrophobic forces. Drug release studies confirmed that the protein corona reduced cumulative drug release by 6%. Antibacterial assays confirmed slightly reduced efficacy against both strains aligning with the reduced cumulative drug release.
conclusionsThis study demonstrated that protein corona formation on dual-surfactant SLNs is strongly influenced by surface charge and surfactant composition and in turn modulates drug release dynamics. The protein corona was shown to modulate drug release with potential implications for antibacterial efficacy. These findings highlight the importance of tailoring surface properties to control protein-nanoparticle interactions thus providing insight into the design of lipid-based nanoparticles for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.